Janelle M Fassbender Adeniran1, Denis Jusufbegovic1, Shlomit Schaal2. 1. a Department of Ophthalmology and Visual Sciences , University of Louisville School of Medicine, University of Louisville , Louisville , Kentucky , USA. 2. b Department of Ophthalmology and Visual Sciences , University of Massachusetts School of Medicine , Worcester , Massachusetts , USA.
Abstract
PURPOSE: Expanding indications for use, and overall increased use of the slow-release dexamethasone (DEX) implant yields an opportunity to study the reported ocular side-effects and adverse events associated with this drug. METHODS: A PubMed.gov (US National Library of Medicine, National Institutes of Health) review of literature for the search terms, "Ozurdex and complication," through December 2015. RESULTS: Ocular hypertension and cataract are the main long-term sequelae identified in large, randomized clinical trials. Case reports have emerged regarding implant migration, complications with implantation, infection, and posterior segment sequelae, including vitreomacular traction. CONCLUSION: DEX implant overall is well-tolerated and, with careful monitoring, can be a useful adjunct to treating macular edema associated with diabetes, retinal vein occlusion, and chronic uveitis.
PURPOSE: Expanding indications for use, and overall increased use of the slow-release dexamethasone (DEX) implant yields an opportunity to study the reported ocular side-effects and adverse events associated with this drug. METHODS: A PubMed.gov (US National Library of Medicine, National Institutes of Health) review of literature for the search terms, "Ozurdex and complication," through December 2015. RESULTS:Ocular hypertension and cataract are the main long-term sequelae identified in large, randomized clinical trials. Case reports have emerged regarding implant migration, complications with implantation, infection, and posterior segment sequelae, including vitreomacular traction. CONCLUSION:DEX implant overall is well-tolerated and, with careful monitoring, can be a useful adjunct to treating macular edema associated with diabetes, retinal vein occlusion, and chronic uveitis.
Authors: Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader Journal: Drug Deliv Transl Res Date: 2021-06 Impact factor: 4.617
Authors: Marta Zola; Cristina Briamonte; Umberto Lorenzi; Federica Machetta; Federico M Grignolo; Antonio M Fea Journal: Clin Ophthalmol Date: 2017-11-06
Authors: Sepehr Bahadorani; Chelsey Krambeer; Kendall Wannamaker; Wayne Tie; Michael Jansen; Jason Espitia; Jeong-Hyeon Sohn; Michael A Singer Journal: Clin Ophthalmol Date: 2018-04-03